Uplarafenib

BRAF, a protein kinase, plays a crucial role in the human body by regulating cell growth and division. It is a key component of the MAPK signaling pathway, which controls various cellular processes such as proliferation, differentiation, and survival. Mutations in the BRAF gene can lead to abnormal activation of the pathway, resulting in uncontrolled cell growth and the development of certain cancers, particularly melanoma. Targeting BRAF mutations with specific inhibitors has revolutionized the treatment of BRAF-mutant cancers, providing patients with more effective and personalized therapeutic options. Understanding the role of BRAF has significantly advanced our knowledge of cancer biology and paved the way for innovative targeted therapies. BRAF Competitive LandscapeAccording to Patsnap Synapse, as of 27 Sep 2023, there are a total of 51 BRAF drugs worldwide, from 88 organizations, covering 79 indications, and conducting 1761 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The analysis of the current competitive landscape of target BRAF reveals that Bayer AG is the leading company in terms of R&D progress, with drugs in multiple phases of development. Several companies, including Roche Holding AG, Pfizer Inc., Novartis AG, and Pierre Fabre Participations SAS, have also made significant progress in their R&D efforts. Drugs under the target BRAF have been approved for various indications, including Melanoma, Colorectal Cancer, Hepatocellular Carcinoma, and Non-Small Cell Lung Cancer. Small molecule drugs, PROTACs, and biosimilars like Monoclonal antibodies and Antibody drug conjugates (ADCs) are progressing rapidly. The United States, European Union, Japan, and China are the countries/locations with the highest development activity. China has shown notable progress in the development of drugs under the target BRAF. Overall, the target BRAF presents a competitive landscape with multiple companies and drug types vying for success in various indications and countries/locations. Key drug: EncorafenibEncorafenib is a small molecule drug that primarily targets the BRAF protein. It has been developed by Array BioPharma, Inc. and has received approval for use in various therapeutic areas. These areas include neoplasms, skin and musculoskeletal diseases, immune system diseases, nervous system diseases, cardiovascular diseases, etc. The drug has shown efficacy in treating several types of cancer, including colorectal cancer, metastatic colorectal carcinoma, metastatic melanoma, melanoma, BRAF V600E mutant non-small cell lung cancer, etc. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Encorafenib has achieved the highest phase of development, which is approved globally. In China, it is currently in phase 3 of development. The drug received its first approval in the United States in June 2018. It is worth noting that Encorafenib is regulated as an orphan drug, indicating its potential to treat rare diseases or conditions. In summary, Encorafenib is a small molecule drug developed by Array BioPharma, Inc. It targets the BRAF protein and has been approved for use in various therapeutic areas, including multiple types of cancer. It has achieved the highest phase of development globally and is currently in phase 3 in China. The drug received its first approval in the United States in 2018 and is regulated as an orphan drug. HLX-208HLX-208 is a small molecule drug that targets BRAF, a protein involved in cell signaling pathways. It is being developed by Suzhou NeuPharman Co. Ltd., a pharmaceutical company specializing in biomedicine. The drug is currently in phase 3 of clinical trials globally, indicating that it has progressed through earlier stages of development and is now being tested for its safety and efficacy in a larger population. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. HLX-208 has shown potential in treating a wide range of therapeutic areas, including neoplasms (abnormal growth of cells), respiratory diseases, nervous system diseases, digestive system disorders, hemic and lymphatic diseases, and skin and musculoskeletal diseases. This suggests that the drug may have a broad spectrum of activity and could be beneficial in various medical conditions. The active indications for HLX-208 include solid tumors, brain cancer, Langerhans-cell histiocytosis, non-small cell lung cancer, colorectal cancer, melanoma, BRAF V600E mutant non-small cell lung cancer, and anaplastic thyroid carcinoma. These indications cover a range of cancer types, indicating that HLX-208 may have potential as an anti-cancer therapy. One notable aspect of HLX-208 is its regulatory status as a breakthrough therapy. Breakthrough therapy designation is granted by regulatory authorities, such as the U.S. Food and Drug Administration (FDA), to expedite the development and review of drugs that show substantial improvement over existing treatments for serious or life-threatening conditions. This designation highlights the potential of HLX-208 to address unmet medical needs and suggests that it may have significant clinical benefits. In summary, HLX-208 has shown potential in treating various therapeutic areas, particularly in the field of oncology, with active indications including solid tumors, brain cancer, and non-small cell lung cancer. Its breakthrough therapy designation further emphasizes its potential as an innovative and promising treatment option.

SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 interim results. In the first half of 2023, Henlius reported a boost in operating profits of RMB240.0 million and revenues of RMB2.5005 billion, up by 93.9% YoY, driven by growth in core oncology products. HANQUYOU (trastuzumab) and HANSIZHUANG (anti-PD-1 mAb) recorded sales of RMB1.2767 billion and RMB556.3 million, respectively. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. To date, 5 self-developed products have been launched, reaching more than 40 markets and benefiting over 450,000 patients. Over 10 marketing applications have been accepted for review in China, the United States (U.S.), the European Union (EU), Brazil, Canada, Indonesia, Singapore and other countries and regions. While accelerating global expansion, Henlius continues to invest in innovation with total spending on R&D hitting RMB673.8 million in the first half of 2023. Wenjie Zhang, Chairman and Executive Director of Henlius, remarked: "During the first half of 2023, Henlius achieved a rather remarkable milestone, becoming profitable for the first time in half a year. In particular, HANQUYOU and HANSIZHUANG have led to a jump in total revenue. As we progressed toward self-financing and increased momentum, we optimized our internal operations, refined our systems, and deepened our moats, thus laying the groundwork for long-term sustainable and high-quality growth to keep up in the global race." Jason Zhu, Chief Executive Officer, President and Chief Financial Officer, said: "Innovation and collaboration have allowed us to penetrate markets and expand with momentum. Moreover, lean operations have enabled us to unleash new growth opportunities and reach beyond our own borders. As we progress, we will maintain an innovative outlook and work closely with our partners to benefit patients worldwide." Global sales on an unstoppable growth streak In the first half of 2023, Henlius achieved a total sales revenue at a record high of approximately RMB2.1529 billion increased by 82.2% YoY, with its ever-increasing self-supporting capability, driving the company into a new stage of sustainable development. The company has established a professional and efficient commercial team to build a business presence in the China market and drive the market penetration on the in-house products HANQUYOU, HANSIZHUANG and HANBEITAI (bevacizumab). In the first half of 2023, these core products of the company gained sales revenue of RMB1.2767 billion, RMB556.3 million and RMB44.9 million, respectively. In addition, the company received a profit-sharing of RMB254.1 million and RMB20.8 million for HANLIKANG (rituximab) and HANDAYUAN (adalimumab) respectively. Henlius' core oncology product, HANQUYOU (trastuzumab, trade name in Europe: Zercepac®, trade name in Australia: Tuzucip® and Trastucip®), continues to grow at a rapid pace and achieved global sales of approximately RMB1.2767 billion in the first half of 2023, up by 57.1% YoY. Specifically, its market share has been further expanded in China. Since March 2023, the monthly sales in Chinese mainland have exceeded RMB200 million. During the reporting period, HANQUYOU has recorded a domestic sales revenue of RMB1.2471 billion, representing an increase of 55.8% YoY. Overseas revenue from product sales and licensing recorded RMB32.8 million approximately, up by 120.1% YoY. Henlius has been actively promoting the global commercialization of HANQUYOU, resulting in its approval in more than 40 countries, including China, the UK, Switzerland, Australia, Singapore, Argentina, and Saudi Arabia, which makes it the China-developed biosimilar with the most marketing approvals. Notably, the Biologics License Application (BLA) for HANQUYOU has been accepted by the U.S. Food and Drug Administration (FDA) and is expected to approve in the second half of the year and to further cover mainstream biopharmaceutical markets and benefit more patients around the world. HANSIZHUANG (serplulimab), the first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC), has achieved total sales revenue of RMB556.3 million in the first half of 2023. Its monthly sales in Chinese mainland have exceeded RMB100 million since March 2023, a year after its launch. At present, HANSIZHUANG has been approved for 3 indications in China including MSI-H solid tumour, squamous non-small cell lung cancer (sqNSCLC) and extensive stage small cell lung cancer (ES-SCLC). Up to date, HANSIZHUANG has completed the tendering process in 29 provinces, and was included into customized commercial medical insurance in 17 cities and provinces, benefitting over 34,000 patients. On the other hand, the New Drug Applications (NDAs) for HANSIZHUANG in the first-line treatment of esophageal squamous cell carcinoma (ESCC) has been accepted by the NMPA in China, with a decision expected in the second half of 2023. If approved, ESCC will be the fourth disease indication for HANSIZHUANG. The company also plans to submit NDA for HANSIZHUANG in the first-line treatment of non-squamous non-small cell lung cancer (nsNSCLC) in the second half of 2023. Furthermore, the company is advancing the commercialization of HANSIZHUANG on overseas markets at high speed. The European Medicines Agency (EMA) has validated the application for HANSIZHUANG and is expected to be approved in the first half of 2024. The company also plans to submit BLA to the U.S. FDA in 2024. In the first half of 2023, the company continued to strengthen, broaden, and deepen its business development around the world, generating approximately RMB347.57 million in overseas licensing and other revenue, an increase of 222.5% YoY. The company joined hands with international partners such as Accord, Abbott, Boston Oncology, Getz Pharma, Elea, Eurofarma, KGbio and Fosun Pharma to accelerate overseas commercialization of products such as HANQUYOU, HANSIZHUNAG, HANLIKANG, HANDAYUAN, and HANBEITAI in countries and regions including the U.S., the EU, Brazil, Canada, Singapore, and Indonesia. In addition, the company is committed to improving the accessibility of immunotherapies and medicines for autoimmune diseases in emerging markets. During the reporting period, the company reached commercialization collaboration with Boston Oncology for HANLIKANG in 16 Middle East and North Africa (MENA) countries. For the commercialization of HANSIZHUANG, the company expanded its collaboration with KGbio to include 12 MENA countries in addition to the previously agreed 10 ASEAN countries. R&D innovation underpinned future The first half of 2023 saw Henlius continue its differentiated innovation and R&D initiatives, exploring novel targets and molecular mechanisms in more disease areas. As the company continues to deploy its innovation centres in California and Shanghai to optimize its research layout, it also steadily expands its clinical layout worldwide. Currently, Henlius has pro-actively built a diversified and high-quality product pipeline, including over 60 molecules across monoclonal antibody (mAb), bispecific antibody (BsAb), ADC, fusion protein, and small molecule drug conjugate, of which more than 80% are self-developed. During the reporting period, Henlius is conducting over 30 clinical studies for more than 10 products globally, including 8 phase 3 clinical trials. In addition, 1 product has been granted a Breakthrough Therapy Designation (BTD) by the NMPA, 6 clinical trials have made important progress, and the Investigational New Drug Applications (INDs) for 2 potential first-in-class ADC candidates were accepted for review by the NMPA. Henlius has actively expanded its differentiated advantages for HANSIZHUANG and has launched over 10 clinical trials of combination therapy worldwide with over 3,600 subjects enrolled globally. In addition to the launched indications of sqNSCLC and ES-SCLC, Henlius also explored to treat patients with nsNSCLC and limited-stage small cell lung cancer (LS-SCLC), covering the full range of first-line treatments of lung cancers. Over 90% of lung cancer patients are expected to benefit from the therapies. Among them, the first patients in the U.S. and Australia have been dosed in an international multi-centre phase 3 clinical trial of HANSIZHUANG in LS-SCLC in January and April 2023, respectively. The company is also steadily advancing the bridging head-to-head trial in the U.S. to compare HANSIZHUANG to standard of care Atezolizumab (anti-PD-L1 mAb) for the first-line treatment of ES-SCLC. As of now, 38 trial sites have been initiated, which is expected to accelerate the progress of the trial thus propelling the product towards US market approval. In the area of gastrointestinal cancer, the results of HANSIZHUANG for the first-line treatment of ESCC was published in Nature Medicine (IF: 82.9) and also updated at 2023 ASCO Annual Meeting. In addition, PD-1 inhibitors are less explored in neoadjuvant/adjuvant therapies for gastric cancer, and Henlius has led the way with a phase 3 clinical study, striving to benefit gastric cancer patients from the early line of immunotherapy. In the first half of 2023, the company continues to make every effort to promote the global multicentre phase 3 clinical studies for HLX11 (pertuzumab biosimilar), HLX14 (denosumab biosimilar) and HLX04-O (anti-VEGF mAb). The first patient in the U.S. was dosed in phase 3 clinical trials of HLX04-O for wAMD in the first half of 2023. Moreover, the latest clinical results for HLX208 (BRAF V600E small molecule inhibitor), HLX07 (anti-EGFR mAb), HLX22 (anti-HER2 mAb) and HLX26 (anti-LAG-3 mAb) were presented to global academic community. Several potential first-in-class candidates are being fully promoted from discovery to early-stage clinical pipeline. During the reporting period, the phase 1 clinical trial for the company's self-developed HLX51, a novel humanized agonistic anti-OX40 mAb for the treatment of patients with advanced/metastatic solid tumours and lymphomas has been approved by the NMPA. Moreover, the company further strengthened its commitment in innovation and enhanced its Linker-Centric Diversified Conjugate Platforms. Utilizing the self-developed ADC platform Hanjugator, Henlius is actively pursuing clinical trial approval for HLX42 (a novel EGFR-targeting ADC) and HLX43 (a novel PD-L1-targeting ADC). Elevating quality and efficiency, steadfastly pursuing global supply Henlius has been building an integrated and comprehensive production platform to continuously improve the accessibility of its products. The current commercial production capacity is 48,000 litres, and Songjiang First Plant and Xuhui Facility have been officially put into operation, forming synergy, and developing scale effects that allow the company to supply products stably to markets beyond China, including Europe and Latin America. To further meet the global commercial production needs, the company is constructing Songjiang Second Plant, with a total capacity of 96,000 litres in the first phase. In 2026, the total production capacity is expected to reach 144,000 litres. In the first half year of 2023, Henlius made progress in lean operations and the localization of key materials and continued to evolve supply chain sustainability. The company adopted such cutting-edge technologies as Raman Spectroscopy and such system as manufacturing SCADA system. The company has always been upholding the highest quality standards, allowing its products to go global. Xuhui Facility has been certificated by China and the EU GMP while Songjiang First Plant obtained China GMP and the EU Qualified Person (QP) certification. The company's commercial production facilities and supporting quality management system have also passed nearly one hundred on-site inspections and audits conducted by regulatory authorities and international business partners. In July and August 2023, Xuhui Facility received the GMP inspection conducted by PIC/S member the Indonesian Food and Drug Authority ("BPOM") for the production line of HANSIZHUANG and Songjiang First Plant received the Pre-License Inspection (PLI) conducted by the U.S. FDA for the production line of HANQUYOU, respectively. Henlius has always been patient-centred and committed to addressing more unmet clinical needs. The company will continue to improve the efficiency of our business operations and innovation, strengthen partnerships with international partners, and expand its global presence in the future. About Henlius Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 1 has been approved for marketing in overseas markets, 18 indications are approved worldwide, and 3 marketing applications have been accepted for review in China, the U.S., and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Plant certificated by China and the EU GMP and Songjiang First Plant certificated by China GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®, the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumors, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), making it the world's first anti-PD-1 mAb for the first-line treatment of SCLC. Its NDA for the treatment of esophageal squamous cell carcinoma (ESCC) is under review. What's more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets. SOURCE Henlius